Surface Oncology to Present at the Baird 2018 Global Healthcare Conference
The live audio and subsequent archived webcasts of the Company's presentations will be accessible from the Company's investor relations website, investors.surfaceoncology.com.
ABOUT SURFACE ONCOLOGY
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment with lead programs targeting CD47, CD73, CD39 and IL-27. Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. The company has a pipeline of seven novel immunotherapies and a strategic collaboration with Novartis focused on up to three next-generation cancer immunotherapies. For more information, please visit www.surfaceoncology.com.
Ann Stanesa, Ten Bridge Communications
Source: Surface Oncology, Inc.